## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Metmi	inco Limited	
ABN		
43 119	759 349	
•	e entity) give ASX the following info	ormation.
	1 - All issues st complete the relevant sections (attach sh	eets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Convertible Notes
2	Number of *securities issued or to	306 convertible notes

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

number which may be issued

Name of entity

Convertible Notes (CN) issued at \$3000 per note (ASX announcement 15 March 2019).

Convertible Notes (CN) issued in single tranche but converted into fully paid shares in two tranches:

- Tranche 1. = 115 CN issued under existing placement capacity LR 7.1 at a conversion price of \$0.003 per share.
- Tranche 2. = 191 CN (issued as debt) and converted subject to shareholder approval at \$0.003 per share If the Proposed Merger (ASX Announcement 13 March 19) does not proceed the conversion price of the CN will be \$0.002.

Subject to shareholder approval, 1 free option per share exercisable at \$0.004 within 2 years from date of issue will be issued to noteholders

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$3000 per convertible note
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Funds raised will primarily be applied to progress the proposed merger with Andes Resources, undertake geophysical and geochemical work to refine drill targeting at the Chuscal Gold Project in Colombia, and provide working capital
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	None
6d	Number of *securities issued with security holder approval under rule 7.1A	None

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	None	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	178,191,092	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	29 March 2019	
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 1,187,940,614 547,345,422	*Class Ordinary Fully paid shares Options exercise price \$0.011 expiring 1 June 2020

<sup>+</sup> See chapter 19 for defined terms.

9. Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	†Class
12,345,639	Options exercisable at A\$0.08 per Option into Shares on or before 17 May 2019.
12,345,639	Options exercisable at A\$0.08 per Option into Shares on or before 25 May 2019.
46,400,000	Performance Rights (terms and conditions summarised in the notice of AGM announced 26 April 2018)
9,600,000	LTIP Options exercisable at A\$0.016 each on or before 31 December 2019, subject to vesting
9,600,000	LTIP Options exercisable at A\$0.024 each on or before 31 December 2020, subject to vesting
306	Convertible Notes (CN) issued in single tranche but converted into fully paid shares in two tranches:  Tranche 1 = 115 CN issued under existing placement capacity LR 7.1 at a conversion price of \$0.003 per share.  Tranche 2 = 191 CN (issued as debt) and converted subject to shareholder approval at \$0.003 per share If the Proposed Merger (ASX Announcement 13 March 19) does not proceed the conversion price of the CN will be \$0.002.  Subject to shareholder approval there will be 1 free option per share exercisable at \$0.004 within 2 years from date of issue.

10	Dividend	policy	(in	the	case	of	а	trust
	distribution	on polic	y) o	n the	incre	ase	d d	capita
	(interests	)						

N/A			

#### Part 2 - Pro rata issue

11	Is security holder approval required?	

12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the ${}^{\scriptsize +}$ securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
25	If the issue is contingent on security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do security holders sell their entitlements in full through a broker?
31	How do security holders sell part of their entitlements through a broker and accept for the balance?

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32		o security holders dispose of their ments (except by sale through a ')?
33	<sup>+</sup> Issue	date
		uotation of securities mplete this section if you are applying for quotation of securities
34	Type (tick o	of *securities one)
(a)	✓	<sup>+</sup> Securities described in Part 1
(b)		All other *securities
		Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entitio	es tha	t have ticked box 34(a)
Additio	onal sec	curities forming a new class of securities
Tick to		e you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders – see attachment
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories – see attachment 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37

04/03/2013 Appendix 3B Page 7

A copy of any trust deed for the additional \*securities

<sup>+</sup> See chapter 19 for defined terms.

### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number	Ciass

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  \*securities to be quoted under section 1019B of the Corporations Act at the 
  time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 1st April 2019

(Company secretary)

Print name: Geoffre

== == == ==

Wedner

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital					
Step 1: Calculate "A", the base figure fi calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	146,280,344				
<ul> <li>Number of fully paid †ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid †ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid †ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid †ordinary securities cancelled during that 12 month period</li> </ul>	694,831,892 – Entitlement Offer (24/4/18) under Exception 1 of LR7.2  2,702,152 – Lanstead share issue (30/04/18) ratified AGM 28 May 2018 - LR 7.4  68,734,589 - Placement 22 May Placement ratified at EGM at 14 September - LR 7.4  88,867,687 shares - Entitlement offer (on or about 18/12/2018) - Exception 1 of LR 7.2  135,000,000 shares- placement 18 <sup>th</sup> October approved at 24 <sup>th</sup> December 2018 EGM-LR 7.4  23,950 shares from conversion of 23,950 Listed options with expiry date 01/06/2020 and an exercise price of \$0.011 per share  51,500,000 shares from Prospectus Placement Shortfall issued at \$0.003 per share (Rights Issue Prospectus closed 14 December 2018)				
"A"	1,187.940,614				

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	178,191,092
Step 3: Calculate "C", the amount of pl has already been used	acement capacity under rule 7.1 that
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
Under an exception in rule 7.2	
Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	
"C"	
Step 4: Subtract "C" from ["A" x "B"] to capacity under rule 7.1	calculate remaining placement
"A" x 0.15	178,191,092
Note: number must be same as shown in Step 2	
Subtract "C"	0
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	178,191,092
	[Note: this is the remaining placement capaci under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10		
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.